Both penicillin and amoxycillin should be tested in antimicrobial surveillance for Streptococcus pneumoniae  by Garau, J.
CORRESPONDENCE 10.1111/j.1469-0691.2005.01130.x
Both penicillin and amoxycillin should be
tested in antimicrobial surveillance for
Streptococcus pneumoniae
The recently published [1] surveillance recom-
mendations of the ESCMID Study Group for
Antimicrobial Resistance Surveillance (ESGARS)
state that ‘Antibiotics to be included in surveil-
lance studies should be selected in such a way as
to ensure the highest sensitivity in detecting the
possible presence of a particular antibiotic resist-
ance mechanism’. This is appropriate if the goal of
the surveillance is purely epidemiological, i.e.,
designed to monitor the presence of resistance
mechanisms, but is inappropriate if the goal of the
surveillance is to provide clinically relevant infor-
mation to clinicians, particularly for the selection
of antimicrobial agents for use in empirical
therapy. The authors also state that the informa-
tion obtained from the ‘sentinel’ antibiotics can be
used to ‘infer’ the activity of other agents, and that
this information should be provided to clinicians,
‘who do not necessarily need to be aware of all the
details regarding the method of inference and its
application’. While this method may be adequate
for some antimicrobial agents, it may not be
appropriate to use penicillin resistance to predict
the clinically relevant activity of amoxycillin.
Streptococcus pneumoniae is one of the most
common bacterial pathogens recovered from
patients with community-acquired pneumonia,
acute bacterial sinusitis, acute exacerbations of
chronic bronchitis, acute otitis media, bacterae-
mia and meningitis. The 1998–2000 Alexander
Project demonstrated penicillin resistance rates
of 41% and 26% in France and Spain, respect-
ively [2]. Penicillin-resistant isolates of S. pneu-
moniae (PRSP) are often resistant to other
antimicrobial agents prescribed commonly, such
as macrolides, trimethoprim–sulphamethoxazole
and the oral cephalosporins, further limiting the
treatment options available to physicians. In
western Europe, 62% of PRSP isolates were also
resistant to macrolides, and 92% were resistant
to trimethoprim–sulphamethoxazole. However,
only 8% of PRSP isolates from western Europe
were resistant to amoxycillin. In addition,
amoxycillin was the only non-quinolone agent
tested that had in-vitro activity for ‡ 90% of the
S. pneumoniae isolates tested in all of the coun-
tries analysed [2].
It is also inappropriate to use penicillin MICs to
predict the MICs of amoxycillin, since these are
not identical and may differ by one or more
dilutions. This is especially signiﬁcant for isolates
with MICs near the penicillin resistance break-
point of ‡ 2 mg ⁄L, as such isolates often have
MICs that are one dilution higher or lower for
amoxycillin, depending on the precise penicillin-
binding protein mutation present.
The key difference between oral amoxycillin
and oral penicillin is the pharmacokinetic proﬁle.
Oral amoxycillin achieves markedly higher serum
concentrations than does penicillin. This is be-
cause amoxycillin is stable in the presence of
gastric acid and is absorbed readily after oral
administration. Penicillin is less stable in gastric
acid and only c. 30% is absorbed into the blood
after oral administration. In addition, the protein
binding of amoxycillin is only c. 17% compared to
80% for penicillin V, so there is signiﬁcantly more
amoxycillin to act on infecting pathogens [3–5].
The key pharmacokinetic ⁄pharmacodynamic
parameter correlating with efﬁcacy of the
b-lactams is the period of time for which serum
levels remain above the MIC for the infecting
pathogen (T > MIC). For b-lactams in general, a
T > MIC that is ‡ 40% of the dosing interval is
predictive of efﬁcacy; however, efﬁcacy was
demonstrated with amoxycillin when the
T > MIC was c. 35–40% of the dosing interval in
an animal model of respiratory tract infection [6].
Many amoxycillin formulations prescribed com-
monly (including 875 mg twice-daily, 875 mg
three-times-daily and 500 mg three-times-daily)
provide a T > MIC that is ‡ 40% of the dosing
interval for isolates with an MIC of 2 mg ⁄L. This
corresponds with the NCCLS susceptibility break-
point for S. pneumoniae, which was based on the
pharmacokinetic ⁄pharmacodynamic proﬁle of
amoxycillin, proven efﬁcacy in animal models
against S. pneumoniae isolates with MICs of
2 mg ⁄L, and studies demonstrating clinical efﬁc-
acy in patients infected with S. pneumoniae strains
with MICs £ 2 mg ⁄L [7].
At the NCCLS susceptibility breakpoint of
£ 2 mg ⁄L, penicillin-intermediate isolates, as well
as most penicillin-resistant isolates, are consid-
ered susceptible to amoxycillin. This becomes
signiﬁcant in countries where high-dose formula-
tions of amoxycillin, or amoxycillin-containing
agents such as Augmentin SR (2000 ⁄ 125 mg
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twice-daily) or Augmentin ES-600, are approved.
These high-dose formulations provide an amoxy-
cillin T > MIC of 46–49% of the dosing interval
for isolates with amoxycillin MICs of 4 mg ⁄L,
thereby providing coverage for an even larger
percentage of PRSP isolates.
The efﬁcacy of amoxycillin against PRSP has
also been demonstrated in the clinic. In a large
phase III clinical programme that included stud-
ies of community-acquired pneumonia, acute
bacterial sinusitis and acute exacerbations of
chronic bronchitis, 50 (96.1%) of 52 patients with
PRSP infection, including 13 of 15 isolates with
amoxycillin MICs of 4–8 mg ⁄L, were treated
successfully with amoxycillin–clavulanate 2000 ⁄
125 mg twice-daily [8]. In paediatric phase
III otitis media studies, Augmentin ES-600
(90 ⁄ 6.4 mg ⁄ kg ⁄day) eradicated 31 (91%) of 34
PRSP isolates by the primary endpoint visit
(on-therapy) [9].
In conclusion, in an era of increased resistance
to many of the antimicrobial agents used com-
monly today, treatment options are limited. Peni-
cillin-intermediate and ⁄ or -resistant isolates of
S. pneumoniae that are reported falsely as resistant
to amoxycillin, or amoxycillin-containing formu-
lations, would reduce the availability of treatment
options and could lead to the use of less appro-
priate agents, such as the ﬂuoroquinolones, which
may need to be reserved for treatment failures.
This is a particular concern with paediatric
patients, for whom ﬂuoroquinolones are not
approved for common respiratory tract infections.
Therefore, if surveillance studies on S. pneumoniae
are to be used by clinicians to help determine
therapeutic options, both penicillin and amoxy-
cillin should be tested.
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Performance of the Focus ELISA test for
detection of herpes simplex virus type-
2-speciﬁc antibodies in Chinese STD
patients
Herpes simplex virus type-2 (HSV-2) infection is
one of the most common sexually transmitted
infections, with a signiﬁcantly increased inci-
dence worldwide. Effective intervention has been
complicated, in part, by the absence of methods
to differentiate HSV-1- from HSV-2-infected
individuals accurately and easily. During the
past 15 years, many tests for detecting antibodies
to HSV-1 or HSV-2 have been developed. The
recent article by Ashley-Morrow et al. [1] des-
cribed the performance of the HerpeSelect HSV-2
ELISA (Focus Technologies, Cypress, CA, USA)
in ten different geographical locations. This test
has been introduced into sexually transmitted
disease (STD) services in China, and has also
been used in epidemiological and interventional
projects.
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